Acrux's successful capital raising efforts

Acrux (ASX:ACR) has successfully raised $1.34 million through a Share Purchase Plan. This follows a previous Placement, totaling $4 million before costs. Funds will advance Acrux's topical pharmaceutical projects towards FDA submission.

Overview and future outlook for Acrux

Acrux has completed a successful capital raising, gathering $4 million before costs through a Share Purchase Plan and a prior Placement. The funds will be used to advance four key late-stage pharmaceutical projects towards FDA submission. Shareholders in both fundraising efforts will receive one free attaching option for each share, subject to approval. This demonstrates Acrux’s ongoing commitment to developing its topical pharmaceutical portfolio and readiness for future commercial opportunities. Further details on the attaching options will be provided in upcoming communications.

Executive insights on Acrux's capital strategy

The capital raised will be directed towards the development of Acrux's pipeline of topical pharmaceutical products. Specifically, the funds will help further four key late-stage development projects with contract manufacturers, preparing for FDA dossier submission.